Investing in patient safety | KPMG | SG
close
Share with your friends
Doctors checking tablets

Investing in patient safety

Investing in patient safety

Pharmaceutical companies have a responsibility to demonstrate to healthcare authorities, providers and customers that the medication they sell is safe to use. Up-to-date labeling is a critical part of this duty of care – to communicate any new dosage regimes or side effects.

However, our experience reveals inefficiencies in the way labels are updated, with companies unable to track labels across the supply chain, and long timelines for changing label production and providing replacements. The result is outdated labels, which can compromise patient safety, harm the organization’s reputation and add significant costs of destroying excessive quantities of old packaging.

We spoke to a number of senior regulatory and manufacturing labeling professionals, to understand how they define, report and track medical label implementation. Our subsequent benchmarking study details the complexity of changing labels, and recommends a more optimal approach to timely labeling:

  • Short-term: pharmaceutical companies should aim to optimize processes, achieve better coordination between regulatory and manufacturing functions, and balance swift delivery with cost reduction.
  • Medium-term: involving a transition to new processes, with online updates, and innovations like printing labels at pharmacies.
  • Longer-term: we expect the industry to move towards high-speed packaging to avoid minimum order quantities, along with electronic labeling that enables updates at minimal cost.

Connect with us

Related content